UCB Ventures is a venture capital arm of UCB, a global biopharmaceutical company. It invests in innovative therapeutics and technology platforms.

UCB Ventures

UCB Ventures is the strategic corporate venture fund of UCB Pharma.
Our mission is to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. 
We make long term investments in early stage companies in the US and Europe. 

We are known for our speed and agility, yet thoughtful and sophisticated approach. Above all, we are committed investors, working closely with entrepreneurs to bring out the best in our portfolio companies.

Investment strategy:
We invest in start-ups developing novel therapeutic modalities, platforms/assets that address novel biology, or innovative digital solutions, in areas adjacent to or even beyond UCB's current therapeutic focus. 
We are seeking breakthrough innovations that enable modulation of genetic systems and/or restore cell and tissue homeostasis in the context of disease. 
We consider all therapeutic modalities and are indication agnostic for all platforms.

Syndesi Therapeutics

If you are attending #BioEquityEurope2024, come and meet our CEO, Miquel Vila-Perello and CBO, Gerard Caelles, next week in San Sebastian! 
 
Join Miquel on 13 May, where he will participate on a panel, titled ‘Scaling Up Europe’s Academic Engine in Cell and Gene Therapy' where he will provide his thoughts on the current cell and gene therapy landscape at 11:15 CEST.
 
At 15:45 CEST on 13 May, Miquel will present 🎤 on SpliceBio's proprietary Protein Splicing platform and lead #GeneTherapy program, SB007, where he will provide an update on the Company's latest developments.
 
Schedule a 1-1 meeting with the team at BioEquity via the online partnering portal here https://bit.ly/3JJQ0r1 or reach out directly via LinkedIn.
 
Revolutionizing genetic medicine with its proprietary Protein Splicing platform!
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

We are pleased to announce that our CMO, Aniz Girach, is presenting at the Retinal Cell and Gene Therapy Innovation Summit today! 
 
If you are attending the event, make sure to see Aniz's presentation, titled 'Intein-based dual-AAV gene therapy for Stargardt disease', from 09:50 – 10:05 PDT.
 
Get in touch to arrange a meeting with the team and find out more about SpliceBio's lead #genetherapy program targeting #Stargardtdisease.
 
#biotech #retinaldiseases #lifesciences

Meet us at BioEquity Europe 2024 from 12-14 May in San Sebastian, where our CSO Viki Bockstal, and our Chair of the Board, Jeanne Bolger, are attending.

Viki will be presenting about what we’re doing in the fight against #infectiousdiseases, including #Covid19 and #Dengue, with our highly potent heavy chain-only antibodies. 

Our pipeline addresses the strong societal need for novel antibodies that can protect even the most vulnerable populations, including elderly and immunocompromised, and can be an integral part of pandemic preparedness strategies.

🤝 Request a partnering meeting now: https://lnkd.in/eaw_6uwz

🔬 Learn about our unique heavy chain-only antibody technology and latest research: https://lnkd.in/etaU9RJk

🔗 Join #BioEquity Europe 2024: https://lnkd.in/dzunkQc

#Pharma #Biotech #Networking

We couldn't be more excited for our upcoming move to Unity Campus and to contribute to the growing community on this fantastic, emerging biomedical campus!

🎉 Experienced company builder David Hipkiss joins us as Independent Chair at a pivotal time - we're preparing to start clinical trials with our lead #hearingloss product Rincell-1. 
 
👨🏼‍💻 His extensive experience in business development and fundraising in both private and public company settings will greatly benefit Rinri Therapeutics. David Hipkiss is also Executive Chair at respiratory gene therapy company AlveoGene. 
 
👂Using its proprietary #OSPREY™ platform, Rinri Therapeutics is developing a portfolio of off-the-shelf #regenerative cell therapy products designed to address sensorineural hearing loss, a significant global medical challenge. 
 
For the full press release please go to: https://bit.ly/3UlBdc1
 
#celltherapy UCB Ventures Boehringer Ingelheim Pioneer Group

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 6:46 AM	4b7b54c0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 18, 2024 7:03 PM	003903e8
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	a13c0733
crunchbase profile	general
li profile	general	Jul 18, 2024 6:46 AM	06bf2622
translate crunchbase fundingrounds	general
peers	general	Jul 18, 2024 6:46 AM	aaaac5b5
news basic	general	Jul 18, 2024 6:46 AM	2c2d7ff1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

UCBV

COM:UCBVENTURES

UCB Ventures